Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

被引：0
|
作者：
Daisuke Minakata
Tadao Ishida
Kiyoshi Ando
Rikio Suzuki
Junji Tanaka
Shotaro Hagiwara
Revathi Ananthakrishnan
Shigeki Kuwayama
Mitsufumi Nishio
Yoshinobu Kanda
Kenshi Suzuki
机构：
[1] Jichi Medical University,Division of Hematology, Department of Medicine
[2] Japanese Red Cross Medical Center,Department of Hematology
[3] Tokai University School of Medicine,Department of Hematology and Oncology
[4] Tokyo Women’s Medical University,Department of Hematology
[5] University of Tsukuba,Faculty of Medicine
[6] Bristol Myers Squibb,undefined
[7] Bristol Myers Squibb K.K,undefined
来源：
International Journal of Hematology | 2023年 / 117卷
关键词：
Relapsed/refractory multiple myeloma; CAR T cell therapy; Japanese patients; Idecabtagene-vicleucel; Triple-class exposed;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：729 / 737
页数：8
相关论文
共 50 条
  • [31] HEALTHCARE RESOURCE UTILIZATION AND 2022 COST UPDATE OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN KARMMA
    McGarvey, N.
    Imanak, K.
    Carattini, T.
    Ung, B.
    Campbell, T. B.
    Gitlin, M.
    Patwardhan, P.
    VALUE IN HEALTH, 2023, 26 (06) : S89 - S89
  • [32] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
  • [33] Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
    Shah, Nina
    Munshi, Nikhil C.
    Berdeja, Jesus G.
    Jagannath, Sundar
    Finney, Olivia
    Martin, Nathan
    Agarwal, Amit
    Rowe, Everton
    Campbe, Timothy B.
    San-Miguel, Jesus F.
    BLOOD, 2021, 138
  • [34] Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial
    Weisel, K.
    Einsele, H.
    Goldschmidt, H.
    Delforge, M.
    San Miguel, J.
    Bertin, K. B.
    Tahir, M.
    Lewis, H.
    Wang, J.
    Braverman, J.
    Campbell, T. B.
    Munshi, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 93 - 94
  • [35] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY
    Jesus, San-Miguel
    Noopur, Raje S.
    David, Siegel
    Sundar, Jagannath
    Sagar, Lonial
    Nikhil, Munshi C.
    Philippe, Moreau
    Hartmut, Goldschmidt
    Michele, Cavo
    Anna, Truppel-Hartmann
    Everton, Rowe
    Huang Liping
    Amit, Agarwal
    Julie, Wang
    Timothy, Campbell B.
    Donna, Reece E.
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 77
  • [36] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
    Mancuso, Katia
    Barbato, Simona
    Talarico, Marco
    Tacchetti, Paola
    Zamagni, Elena
    Cavo, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
  • [37] KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
    Delforge, Michel
    Baz, Rachid C.
    Cavo, Michele
    Callander, Natalie S.
    Ghobadi, Armin
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Massaro, Monica
    Ding, Li
    Patel, Payal
    Pittari, Gianfranco
    Novick, Steven
    Giralt, Sergio A.
    Berdeja, Jesus G.
    BLOOD, 2020, 136
  • [38] Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
    Delforge, Michel
    Otero, Paula Rodriguez
    Shah, Nina
    Moshkovich, Olga
    Braverman, Julia
    Dhanda, Devender S.
    Lanar, Sally
    Devlen, Jennifer
    Miera, Matthew
    Gerould, Heather
    Campbell, Timothy B.
    Munshi, Nikhil C.
    LEUKEMIA RESEARCH, 2023, 129
  • [39] Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs)
    Mashadi-Hossein, Afshin
    Rytlewski, Julie
    Shamsuzzaman, Md
    Basudhar, Debashree
    Takhar, Mandeep
    Kostic, Ana
    Campbell, Timothy Brandon
    Manier, Salomon
    Lin, Yi
    Martin, Nathan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
    McGarvey, November
    Carattini, Thomas
    Ung, Brian
    Campbell, Timothy B.
    Imanak, Ken
    Patwardhan, Pallavi
    BLOOD, 2022, 140 : 10947 - 10948
12345